Compare Cenovus Energy Inc (CVE) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cenovus Energy Inc vs Quest Diagnostics Inc — how do they compare? Cenovus Energy Inc trades at $30.21 (market cap $55.00B), while Quest Diagnostics Inc trades at $238.13 (market cap $26.21B). The key difference: Cenovus Energy Inc is far larger — about 2.1× Quest Diagnostics Inc's market cap, and Cenovus Energy Inc pays the higher dividend (2.09%). Which is the better fit depends on your goals.
| CVE | DGX | |
|---|---|---|
Market Cap | $55.00B | $26.21B |
Sector | Energy | Health |
52-Week High | $31.80 | $238.50 |
52-Week Low | $14.83 | $173.49 |
Enterprise Value | $61.08B | $31.97B |
Dividend Yield | 2.09% | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cenovus Energy (CVE) trades at $29.56, up 4.64% with bullish technical momentum. The stock shows strong fundamentals with attractive valuation ratios (P/E 11.56, EV/EBITDA 5.77) and solid profitability (ROE 20.96%). Recent Q2 2026 earnings matched estimates with record oil sands production driving operational strength. Analyst consensus leans positive with 40.7% buy ratings despite mixed quarterly performance.
CVE presents value opportunity with robust cash flow generation and production growth, though faces commodity price volatility risks. Wall Street sentiment remains cautiously optimistic with institutional accumulation supporting upside potential. Key risks include oil price dependency and refining margin pressures that could impact earnings stability.
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
